Glucocorticoid treatment

Phase 3Small molecule

Bristol-Myers Squibb

Glucocorticoid treatment is one of 64 small molecule programs targeting Rheumatic Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseActive, not recruiting

Giant Cell ArteritisActive, not recruiting

Rheumatic DiseasePreclinical

Active, not recruiting

Giant Cell ArteritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

Anjeso

Boehringer Ingelheim

Approved

1 2

Bextra

TThe Searle Company Limited Pakistan

Approved

—3

Oruvail

WWyeth-Lederle Vaccines

COVID-19 Vaccine

2 5

Jascayd

Boehringer Ingelheim

Phase 3

—6

Trexall

Alnylam Pharmaceuticals

Phase 2

1 7

Azulfidine

Pfizer

Phase 2

1 8

Plaquenil

Alnylam Pharmaceuticals

Phase 2

1 9

Arava

Sanofi

Phase 2

1 10

Myfortic

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Recruiting

Rheumatic Disease

NCT02719314

Clinical

Trials by Indication[1]

Giant Cell Arteritis1 trial

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03192969

Rheumatic Disease1 trial

Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis

Recruiting·PProf Dr Frank Buttgereit··NCT02719314·10,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Glucocorticoid treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucocorticoid treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucocorticoid treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Glucocorticoid treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Giant Cell Arteritis1 trial

Rheumatic Disease1 trial

References

Drug Info

Quick Facts

Related News